Aclaris Therapeutics (FRA:8AT) Beginning Cash Position : €36.69 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Beginning Cash Position?

Aclaris Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €36.69 Mil.

Aclaris Therapeutics's quarterly Beginning Cash Position increased from Sep. 2023 (€29.19 Mil) to Dec. 2023 (€35.80 Mil) and increased from Dec. 2023 (€35.80 Mil) to Mar. 2024 (€36.69 Mil).

Aclaris Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€19.53 Mil) to Dec. 2022 (€25.82 Mil) and increased from Dec. 2022 (€25.82 Mil) to Dec. 2023 (€41.52 Mil).

Aclaris Therapeutics Beginning Cash Position Historical Data

The historical data trend for Aclaris Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Beginning Cash Position Chart

Aclaris Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

51.32

29.54

19.53

25.82

41.52

Aclaris Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															42.29	41.28	29.19	35.80	36.69

Aclaris Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Aclaris Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

ACRS:USA

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines